Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Cotinine Assay Rapidly Confirms Nonsmoking Status

By LabMedica International staff writers
Posted on 13 Jan 2014
A novel, rapid and user-friendly diagnostic test provides confirmation that an individual has stopped smoking tobacco cigarettes.

In addition to being healthier, not smoking can significantly reduce the cost of health insurance. More...
However, until recently it has not been easy to prove diagnostically that an individual was a non-smoker.

Toward this end, the British biotech company GFC Diagnostics (Bicester, United Kingdom) has introduced the Saliva SmokeScreen test. The test detects cotinine, a breakdown product of nicotine. Cotinine has an in vivo half-life of approximately 20 hours, and is typically detectable for several days (up to one week) after the use of tobacco. The level of cotinine in the blood is proportionate to the amount of exposure to tobacco smoke, so it is a valuable indicator of tobacco smoke exposure. The newly improved Saliva SmokeScreen assay is more sensitive and specific than its previous version, being reported at 90% and 98% respectively, with an accuracy of 94%.

To test for nicotine exposure the user places the test swab in the mouth to absorb 1.5 mL of saliva. The swab is removed from the mouth, placed inside the plastic collector, and pushed against the grid half way down. This procedure squeezes the saliva into the bottom of the collector. The presence of cotinine causes a color change that is visible after one minute. The optimal time to read the result is six minutes. If read before five minutes, the result will be positive, but less than the correct result. After six minutes, it will be more than the true result.

The Saliva SmokeScreen test has been certified as a tool in a British health insurer's program to verify nonsmoking in their policy holders, so they can qualify for its unique nonsmoker cash back reward. Dr. Graham Cope, technical director at GFC Diagnostics and an honorary senior research fellow at the University of Birmingham (United Kingdom), said, "Smoking is an important risk factor for many chronic diseases, such as respiratory diseases, cardiovascular disease, and diabetes. It also causes blood pressure to rise and is linked with high cholesterol levels. We are pleased the SmokeScreen test has been chosen as the means to monitor smoking in this program."

Related Links:

GFC Diagnostics
University of Birmingham



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.